The American Institute of Biological Sciences (AIBS) joined 45 scientific, academic, and medical stakeholder groups in expressing support for legislation aimed at scaling up efforts to track and respond to coronavirus variants in the United States.

The Coalition for National Science Funding (CNSF) has called on congressional leadership to include $3 billion in emergency relief for the NSF while providing relief to all federal science agencies.

The American Institute of Biological Sciences (AIBS) is pleased to support the nomination of Dr. Eric Lander—a geneticist, molecular biologist, and mathematician—as Director of the White House Office of Science and Technology Policy (OSTP) and presidential science advisor.

The American Institute of Biological Sciences completely condemns the forces that led to the occupation and violence that took place at the US Capitol on January 6, 2021.

On behalf of the scientific, medical, and patient communities dedicated to advancing medical knowledge and improving human health, we congratulate you on your election and urge you, upon taking office, to swiftly rescind the human fetal tissue (HFT) research restrictions and policy changes that the Department of Health and Human Services made in 2019.

AIBS is deeply concerned by this proposal to impose complicated new visa restrictions on international students and urge that the proposed rule be withdrawn in its entirety.

Forty-three scientific societies, including the American Institute of Biological Sciences (AIBS), have written to the National Science Foundation (NSF) to highlight the important role scientific associations have played during the COVID-19 pandemic.

The undersigned scientific societies strongly urge the Administration to rescind its elimination of federal employee training programs related to diversity, equity and inclusion as specified in the Memorandum for the Heads of Executive Departments and Agencies issued September 4th, 2020 and the September 22nd Executive Order on Combating Race and Sex Stereotyping.

As representatives of hundreds of thousands of scientists across the country, we write to urge you to adhere to stringent scientific and medical standards as the Food and Drug Administration (FDA) prepares to assess the safety and efficacy of vaccine candidates that are currently in phase III clinical trials.

As leaders of the nation's scientific societies, we stand ready to work with the National Science Foundation to address and surmount the challenges that COVID-19 poses to the research enterprise. We urge your continued support for the valuable programming we provide and encourage you to foster a culture of innovation in order to meet the short- and long-term needs of the scientific community